pediatric patient / parent

Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH

Original Publication Date
Article Source
External Web Content
Published: Dec 15, 2021 STOCKHOLM, Dec. 15, 2021 /PRNewswire/ -- The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving haemoglobin levels1 Aspaveli will…

AML Management: Feel Better With Food and Physical Activity

Original Publication Date
Article Source
External Web Content
If you’re receiving treatment for acute myeloid leukemia (AML), it probably feels like a lot of things are outside your control. But there are many small choices you can make each day — doable steps that can help you feel better inside and out. “It’s important to have achievable…

Parenting a Child with Bone Marrow Failure Disease - Summer 2021 Conference

Thumbnail for video Watch Now

Topic(s)
Pediatric Bone Marrow Failure Diseases
Presenter(s)
Jennifer Hoag, PhD
When a child is diagnosed with a bone marrow failure disease, often the focus is soley on the child's medical care. This session will help parents, guardians and others who parent children with aplastic anemia, PNH, MDS, AML and other bone marrow failure conditions navigate the…

Swapna Thota, MD

Institution
University of Tennessee
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
As a physician caring for patients with acute leukemias and related disorders, I have a sustained focus on translational research in hematologic malignancies. Genomic sequencing technology revolutionized our understanding of cancer biology. My research focuses on exploring the dynamic changes of tumor immune microenvironment with clonal evolution of myeloid malignancies. Targeting inflammaging of bone marrow to impede clonal evolution is my ultimate professional goal and there by improve the survival rate for leukemia patients. My long-term goal is to develop potentially less toxic targeted

Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Original Publication Date
Article Source
External Web Content
– With this approval, ULTOMIRIS is the first and only medicine approved in the U.S. to treat children and adolescents with PNH – – Approval based on interim results from Phase 3 study showing ULTOMIRIS demonstrated complete terminal complement inhibition through 26 weeks – BOSTON…

RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML

Original Publication Date
Article Source
External Web Content
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American…

Pack your Bags and Head to the Hospital - Hailey's Story

“You will need to pack your bags and head to Children’s Hospital, we think it’s leukemia.”

Only a few days after a Complete Blood Count, Christy, Hailey's mom, heard these words from Hailey’s doctor. Hailey had just started kindergarten.

At summer dance camp, Hailey won the award for “Most Tired.” That puzzled her mom. As kindergarten progressed, Christy noticed the fatigue. She assumed that kindergarten must be exhausting for children. Christmas was approaching when she noticed Hailey’s bruises, in odd places on her body.

Scientists discover two unique subtypes of a prominent mutation in patients with AML

Original Publication Date
Article Source
External Web Content
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) – called NPM1 – that could help predict survival and improve treatment response for patients whose leukemic cells bear…
Subscribe to pediatric patient / parent

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.